Ramkumar Mandalam Sells 23,214 Shares of CryoPort (NASDAQ:CYRX) Stock

CryoPort, Inc. (NASDAQ:CYRX) Director Ramkumar Mandalam sold 23,214 shares of CryoPort stock in a transaction that occurred on Monday, June 8th. The shares were sold at an average price of $15.44, for a total value of $358,424.16. Following the sale, the director directly owned 67,894 shares in the company, valued at approximately $1,048,283.36. The trade was a 25.48% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.

CryoPort Stock Down 1.9%

Shares of CYRX opened at $15.19 on Wednesday. The business’s 50 day moving average price is $12.04 and its 200-day moving average price is $10.22. CryoPort, Inc. has a 52 week low of $6.16 and a 52 week high of $16.73. The stock has a market cap of $765.58 million, a P/E ratio of 11.25 and a beta of 1.90.

CryoPort (NASDAQ:CYRX) last issued its quarterly earnings results on Monday, May 4th. The company reported ($0.23) EPS for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.03). CryoPort had a negative return on equity of 7.92% and a net margin of 41.57%.The company had revenue of $47.80 million during the quarter, compared to the consensus estimate of $44.86 million. On average, equities analysts anticipate that CryoPort, Inc. will post -0.85 EPS for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on CYRX. Needham & Company LLC boosted their price target on CryoPort from $13.00 to $15.00 and gave the stock a “buy” rating in a research report on Tuesday, May 5th. Craig Hallum boosted their price target on CryoPort from $15.00 to $20.00 and gave the stock a “buy” rating in a research report on Wednesday, June 3rd. KeyCorp boosted their price target on CryoPort from $15.00 to $17.00 and gave the stock an “overweight” rating in a research report on Wednesday, May 20th. Jefferies Financial Group set a $13.50 price target on CryoPort in a research report on Monday. Finally, Guggenheim upped their price objective on CryoPort from $11.00 to $12.00 and gave the company a “buy” rating in a research report on Tuesday, May 5th. Eight investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $15.11.

Hedge Funds Weigh In On CryoPort

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. UBS Group AG lifted its position in CryoPort by 6.8% in the 4th quarter. UBS Group AG now owns 1,421,884 shares of the company’s stock valued at $13,650,000 after acquiring an additional 90,363 shares in the last quarter. Mak Capital One LLC bought a new position in shares of CryoPort during the 3rd quarter valued at $7,756,000. First Eagle Investment Management LLC bought a new position in shares of CryoPort during the 4th quarter valued at $2,996,000. Legato Capital Management LLC bought a new position in shares of CryoPort during the 4th quarter valued at $443,000. Finally, Segall Bryant & Hamill LLC bought a new position in shares of CryoPort during the 3rd quarter valued at $652,000. 92.90% of the stock is owned by institutional investors.

CryoPort Company Profile

CryoPort, Inc (NASDAQ: CYRX) is a global provider of temperature-controlled logistics solutions for the life sciences industry. The company specializes in cryogenic shipping for critical biological materials, supporting the development, clinical testing and commercialization of cell and gene therapies, biologics, vaccines and reproductive medicine. By offering end-to-end supply chain management, CryoPort helps ensure the integrity and viability of temperature-sensitive products from point of origin to destination.

CryoPort’s product portfolio includes proprietary cryogenic dry shippers, advanced active and passive thermal packaging, and real-time data monitoring platforms.